ClinicalTrials.gg
Sign In
DrugBiological

Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes clinical trials

studies test it
4
open now
0
in phase 3
0
first study started
2011

How each study uses Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

CAR.CD30 T cells
4
ATLCAR.CD30 cells
3

Studies by the year they started

4 studies that test it; most in 2016 (2)

Studies that test Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes, by start year
YearStudies
20111
20162
20221

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, Non-Hodgkin
2
Hodgkin Disease
1
Neoplasms, Germ Cell and Embryonal
1

Who runs them

Industry 0 · Other 4

UNC Lineberger Comprehensive Cancer Center (4)

Studies

Open first, then newest update. How each study uses Autologous CD30CAR-CD28-CD3zeta-expressing T-Lymphocytes is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 4